Who are aripiprazole long acting injectable formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ropinirole CR-RLS, [11C]raclopride, IM aripiprazole once monthly, Raclopride C11, Ropinirole (Requip), Amisulpride add-on.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aripiprazole-long-acting-injectable-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

aripiprazole long acting injectable formulation — Competitive Intelligence Brief

aripiprazole long acting injectable formulation (aripiprazole long acting injectable formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (dopamine partial agonist). Area: Psychiatry / Neurology.

marketed Atypical antipsychotic (dopamine partial agonist) Dopamine D2 receptor, Dopamine D3 receptor Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

aripiprazole long acting injectable formulation (aripiprazole long acting injectable formulation) — Vanguard Research Group. Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
aripiprazole long acting injectable formulation TARGET	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
Ropinirole (Requip)	Ropinirole (Requip)	St. Luke's-Roosevelt Hospital Center	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
Amisulpride add-on	Amisulpride add-on	National Health Research Institutes, Taiwan	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (dopamine partial agonist) class)

Vanguard Research Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aripiprazole long acting injectable formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-long-acting-injectable-formulation. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab